Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.

@article{Gordon2013AdherenceTA,
  title={Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.},
  author={Stuart Gordon and Eric M Yoshida and Eric J. Lawitz and Bruce R. Bacon and Mark S Sulkowski and Miriam A Davis and Fred P Poordad and J P Bronowicki and Rafael Esteban and Vilma Sniukiene and Margaret H Burroughs and Weiping Deng and Frank J. Dutko and Clifford A. Brass and Janice K. Albrecht and K. Rajender Reddy},
  journal={Alimentary pharmacology & therapeutics},
  year={2013},
  volume={38 1},
  pages={16-27}
}
BACKGROUND Adherence to therapeutic regimens affects the efficacy of peginterferon alfa (P) and ribavirin (R) therapy in patients with chronic hepatitis C virus genotype 1. AIM To determine if medication adherence impacts efficacy [sustained virological response (SVR)] with triple therapy that includes boceprevir (BOC) plus P/R. METHODS Adherence was determined in two Phase 3 clinical studies with BOC: SPRINT-2 (previously untreated patients) and RESPOND-2 (patients who failed previous… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…